WO1998010757A9 - The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity - Google Patents
The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicityInfo
- Publication number
- WO1998010757A9 WO1998010757A9 PCT/US1997/016605 US9716605W WO9810757A9 WO 1998010757 A9 WO1998010757 A9 WO 1998010757A9 US 9716605 W US9716605 W US 9716605W WO 9810757 A9 WO9810757 A9 WO 9810757A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aminoglycoside
- functional
- antibiotic
- nmda
- antagonist
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N NMDA Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title claims abstract description 51
- 206010033109 Ototoxicity Diseases 0.000 title claims abstract description 49
- 231100000262 ototoxicity Toxicity 0.000 title claims abstract description 49
- 230000003042 antagnostic Effects 0.000 title abstract description 51
- 239000005557 antagonist Substances 0.000 title abstract description 51
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims abstract description 28
- 230000027455 binding Effects 0.000 claims description 50
- 229960004927 neomycin Drugs 0.000 claims description 41
- UYNVMODNBIQBMV-UHFFFAOYSA-N Ifenprodil Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 claims description 40
- LBOJYSIDWZQNJS-CVEARBPZSA-N Dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 claims description 38
- 229960003998 ifenprodil Drugs 0.000 claims description 38
- 229950004794 Dizocilpine Drugs 0.000 claims description 36
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 claims description 36
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 claims description 36
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 25
- 229960000318 kanamycin Drugs 0.000 claims description 25
- 230000003115 biocidal Effects 0.000 claims description 23
- 229920000768 polyamine Polymers 0.000 claims description 19
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 19
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims description 17
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 14
- 229960005322 Streptomycin Drugs 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
- 229940063675 spermine Drugs 0.000 claims description 7
- -1 quinoline compound Chemical class 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 4
- 230000002730 additional Effects 0.000 claims description 4
- 229960003299 ketamine Drugs 0.000 claims description 4
- 229960004640 memantine Drugs 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- 101700015952 CKG Proteins 0.000 claims description 3
- HTBKFGWATIYCSF-QGXIKSNHSA-N Conantokin G Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN HTBKFGWATIYCSF-QGXIKSNHSA-N 0.000 claims description 3
- 230000000875 corresponding Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- HGMDNMBBCKDWTQ-UHFFFAOYSA-N 1,4-diguanidinobutane Chemical compound NC(=N)NCCCCNC(N)=N HGMDNMBBCKDWTQ-UHFFFAOYSA-N 0.000 claims description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N 2-Indolecarboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 claims description 2
- UAWVRVFHMOSAPU-UHFFFAOYSA-N 7-Chlorokynurenic acid Chemical compound C1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 UAWVRVFHMOSAPU-UHFFFAOYSA-N 0.000 claims description 2
- RPNUMPOLZDHAAY-UHFFFAOYSA-N DETA Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims description 2
- GGUSQTSTQSHJAH-UHFFFAOYSA-N Eliprodil Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 claims description 2
- 229950005455 Eliprodil Drugs 0.000 claims description 2
- JUZZEWSCNBCFRL-UHFFFAOYSA-N Tenocyclidine Chemical compound C1CCCCN1C1(C=2SC=CC=2)CCCCC1 JUZZEWSCNBCFRL-UHFFFAOYSA-N 0.000 claims description 2
- 230000002860 competitive Effects 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- ZEFQYTSQDVUMEU-GQCTYLIASA-N (E)-2-amino-4-(phosphonomethyl)hept-3-enoic acid Chemical compound CCC\C(CP(O)(O)=O)=C/C(N)C(O)=O ZEFQYTSQDVUMEU-GQCTYLIASA-N 0.000 claims 1
- BDYHNCZIGYIOGJ-DUXPYHPUSA-N (E)-2-amino-4-methyl-5-phosphonopent-3-enoic acid Chemical compound OP(=O)(O)CC(/C)=C/C(N)C(O)=O BDYHNCZIGYIOGJ-DUXPYHPUSA-N 0.000 claims 1
- 230000036499 Half live Effects 0.000 claims 1
- 208000004559 Hearing Loss Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 14
- 206010011878 Deafness Diseases 0.000 abstract description 11
- 206010011879 Hearing loss Diseases 0.000 abstract description 10
- 231100000888 hearing loss Toxicity 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 231100000896 loss of balance Toxicity 0.000 abstract description 4
- 241000700198 Cavia Species 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 230000035492 administration Effects 0.000 description 25
- LBOJYSIDWZQNJS-UHFFFAOYSA-N Neurogard Chemical compound C12=CC=CC=C2C2(C)C3=CC=CC=C3CC1N2 LBOJYSIDWZQNJS-UHFFFAOYSA-N 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 210000002768 hair cell Anatomy 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 230000002970 ototoxic Effects 0.000 description 14
- 231100000199 ototoxic Toxicity 0.000 description 13
- 230000011514 reflex Effects 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 102000004310 Ion Channels Human genes 0.000 description 10
- 108090000862 Ion Channels Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 210000003477 Cochlea Anatomy 0.000 description 9
- 230000002708 enhancing Effects 0.000 description 8
- 230000000051 modifying Effects 0.000 description 8
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 6
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 6
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 6
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 6
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000002596 correlated Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229940079866 intestinal antibiotics Drugs 0.000 description 6
- 210000002569 neurons Anatomy 0.000 description 6
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 6
- 230000036515 potency Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- UNFWWIHTNXNPBV-WXKVUWSESA-N Actinospectacin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 210000004027 cells Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002287 radioligand Substances 0.000 description 5
- 230000001603 reducing Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 229960000268 spectinomycin Drugs 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 4
- 210000002985 Organ of Corti Anatomy 0.000 description 4
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 229960004821 amikacin Drugs 0.000 description 4
- 210000003030 auditory receptor cell Anatomy 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001684 chronic Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 230000000977 initiatory Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229950010883 phencyclidine Drugs 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 210000004379 Membranes Anatomy 0.000 description 3
- 210000004129 Prosencephalon Anatomy 0.000 description 3
- 210000000225 Synapses Anatomy 0.000 description 3
- 230000002051 biphasic Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000003248 quinolines Chemical class 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229940009098 Aspartate Drugs 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 229960002327 Chloral Hydrate Drugs 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N Chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- JCAIWDXKLCEQEO-LXOWHHAPSA-N Copalyl diphosphate Natural products [P@@](=O)(OP(=O)(O)O)(OC/C=C(\CC[C@H]1C(=C)CC[C@H]2C(C)(C)CCC[C@@]12C)/C)O JCAIWDXKLCEQEO-LXOWHHAPSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 210000001323 Spiral Ganglion Anatomy 0.000 description 2
- 229960000707 Tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002238 attenuated Effects 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 231100000890 cochlea damage Toxicity 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 230000003492 excitotoxic Effects 0.000 description 2
- 231100000318 excitotoxic Toxicity 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960000204 ifenprodil tartrate Drugs 0.000 description 2
- 230000001771 impaired Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 230000003204 osmotic Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000962 vestibulotoxicity Toxicity 0.000 description 2
- VOKSWYLNZZRQPF-CCKFTAQKSA-N (+)-Pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)[C@H](C)[C@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-CCKFTAQKSA-N 0.000 description 1
- GEDVVYWLPUPJJZ-UHFFFAOYSA-N (7-amino-8-methylphenothiazin-3-ylidene)-dimethylazanium;chloride Chemical compound [Cl-].N1=C2C=CC(=[N+](C)C)C=C2SC2=C1C=C(C)C(N)=C2 GEDVVYWLPUPJJZ-UHFFFAOYSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(Z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N 2-hydroxyethyl 2-methylacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 210000000721 Basilar Membrane Anatomy 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 210000003710 Cerebral Cortex Anatomy 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 241000222239 Colletotrichum truncatum Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 210000000883 Ear, External Anatomy 0.000 description 1
- 241000508725 Elymus repens Species 0.000 description 1
- 206010014665 Endocarditis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229960002064 Kanamycin Sulfate Drugs 0.000 description 1
- 241000408521 Lucida Species 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241000187708 Micromonospora Species 0.000 description 1
- 241000122159 Modiolus Species 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N Neomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229940053050 Neomycin Sulfate Drugs 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- 210000004049 Perilymph Anatomy 0.000 description 1
- 210000003200 Peritoneal Cavity Anatomy 0.000 description 1
- 241001463913 Pinna Species 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- GUBXYMKIJFOYOA-YMGPVYFXSA-N [(2R)-2-formyloxy-3-[hydroxy-[(2R,3S,5R,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] formate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(=O)OC[C@@H](COC=O)OC=O)[C@H](O)[C@@H]1O GUBXYMKIJFOYOA-YMGPVYFXSA-N 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003281 allosteric Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002547 anomalous Effects 0.000 description 1
- 229940111121 antirheumatic drugs Quinolines Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000001174 ascending Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 231100000881 cochleotoxicity Toxicity 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000002964 excitative Effects 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000848 glutamatergic Effects 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 102000004108 neurotransmitter receptors Human genes 0.000 description 1
- 108090000590 neurotransmitter receptors Proteins 0.000 description 1
- 231100001098 no ototoxicity Toxicity 0.000 description 1
- 230000036963 noncompetitive Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000452 restraining Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
Definitions
- the present invention relates to the use of a class of compounds to ameliorate and prevent aminoglycoside-induced ototoxicity. These compounds fall within the group of substances which reduce activity at N- methyl-D-aspartate (NMDA) receptors and are referred to as functional NMDA antagonists.
- NMDA N- methyl-D-aspartate
- Aminoglycoside antibiotics are polycations consisting of amino sugars connected to an aminocyclitol nucleus, and are derived from the fungi Strep tomyces and Micromonospora (1,2). Aminoglycoside antibiotics potently inhibit protein synthesis at the ribosomal level and compromise membrane integrity in a range of Gram-negative and some Gram-positive bacteria. These agents are clinically valued for their rapid onset of bacteriocidal activity, synergism with ⁇ -lactam antibiotics and low cost. They are commonly used to treat Gram-negative sepsis, endocarditis, nosocomial infections and tuberculosis .
- NMDA receptor mRNA in the synapses between cochlear hair cells and spiral ganglion neurons (9, 10) , and of the enhancement of radioligand binding to the NMDA receptor by aminoglycosides in a polyamine-like fashion (11) . It is also known that there are a number of isoforms of NMDA
- NMDA receptor mRNA did not discriminate among receptor isoforms, and, therefore, whether the isoforms in the tissues tested were sensitive or insensitive to polyamines. Moreover, since not all NMDA
- One object of the invention relates to the prevention and/or amelioration of aminoglycoside induced ototoxicity by use of NMDA antagonists.
- Another object of the invention relates to the use of functional NMDA antagonists to provide substantial protection against aminoglycoside- induced ototoxicity in a patient .
- a further object of the invention relates to the use of NMDA antagonists as a pharmaceutical composition in the prevention or amelioration of aminoglycoside induced
- Yet another object of the invention is to provide an improved method of antibiotic treatment to prevent aminoglycoside-induced ototoxicity comprising the step of administering a therapeutically effective amount of a NMDA antagonist in combination with an aminoglycoside antibiotic .
- An additional object of the invention relates to a bacteriocidal antibiotic composition
- a bacteriocidal antibiotic composition comprising a therapeutically effective amount of an aminoglycoside and functional NMDA antagonists to control ototoxicity.
- aminoglycoside antibiotics are bacteriocidal agents whose clinical utility is limited by their ototoxicity. This ototoxicity can result in significant 5 hearing loss and/or a loss of balance.
- NMDA receptors were identified at the cochlear hair cell-spiral ganglion neuron synapse. Further, a recent in vi tro study demonstrated the ability of aminoglycosides to modulate NMDA receptor function via the polyamine site.
- present invention relates to the discovery that enhancement of glutamatergic neurotransmission at the hair cell synapse by aminoglycosides results in necrosis of either the hair cells and/or spiral ganglion neurons through excitotoxic mechanisms (12) which could be
- the present invention relates to the identification of functional NMDA antagonists, which are capable of ameliorating or preventing aminoglycoside- induced hearing loss or loss of balance.
- These o antagonists act at a variety of sites on NMDA receptors including, but not limited to, the polyamine binding site, the ion channel, the glycine binding site and the glutamate binding site.
- the effect of these functional NMDA antagonists is to reduce the activity of NMDA o ⁇ - receptors.
- Preferred compounds of the present invention comprise quinoline and non-quinoline functional NMDA antagonists .
- the more preferred compounds are non- quinolines .
- the compounds of the present invention are useful as a pharmaceutical composition either alone in the amelioration or prevention of aminoglycoside- induced ototoxicity, (as in the treatment of patients receiving aminoglycosides) , or in combination with an aminoglycoside in order to prevent ototoxicity and simultaneously provide bacteriocidal activity.
- the present invention demonstrates that concurrent administration of functional NMDA antagonists and aminoglycosides limits cochlear damage, vestibular damage and hearing impairment produced by aminoglycoside antibiotics.
- Methods of using such pharmaceutical compounds in treating aminoglycoside- induced ototoxicity are also provided. These methods include an improved method of aminoglycoside antibiotic treatment which prevents aminoglycoside-induced ototoxicity.
- aminoglycosides to modulate ligand binding to NMDA receptors also provides an effective screen for developing new aminoglycoside antibiotics with reduced ototoxic potential.
- FIG. 1 Schematic diagram of the NMDA receptor complex.
- the NMDA receptor complex is composed of several protein subunits clustered in such a way as to form a channel, which, when opened, is permeable to sodium and calcium ions. Excessive entry of calcium ions into a hair cell or neuron can result in the death of that cell .
- Surrounding and within the channel are numerous modulatory sites, including recognition sites for: glutamate; ° glycine; multiple polyamine associated sites (one within the ion channel) ; and the dizocilpine (or MK-801) binding site within the ion channel .
- NMDA antagonists limit neomycin- induced decrements in the Preyer reflex response to 5 (Panel A), 7 (Panel B) , and 10 (Panel C) kHz tones.
- Preyer reflex is a measure of hearing threshold well known in the art (17, 18) .
- Two groups of guinea pigs received daily subcutaneous injections of either saline (•) or neomycin (O) for 14 days.
- Two other groups of guinea pigs received subcutaneous injections of neomycin together with either dizocilpine (1 mg/kg/d, ⁇ ) or ifenprodil (10 mg/kg/d, A) delivered by subcutaneous osmotic minipumps .
- the Preyer reflex was examined in these animals 2 weeks after completing the antibiotic regimen.
- the "noise floor” is a sound level below ° that which can be detected by the measuring device at a particular frequency.
- FIG. 4 A summary of the changes in inner (A) and outer (B) hair cell populations of cochleae from 0 individual guinea pigs treated with neomycin ( ⁇ ) , neomycin + dizocilpine (•) , or neomycin + ifenprodil (A) in serial sections cut through the organ of Corti. Results are expressed as the percentage of cells missing compared to normal guinea pig cochleae. Note the total loss of both 5 inner and outer hair cells between 13 to 18 mm from the apex of the cochlea in the neomycin treated guinea pig.
- the NMDA receptor is one of the major subtypes of fast excitatory neurotransmitter receptors in the mammalian central nervous system. These receptors are activated by the acidic amino acids glutamate and aspartate .
- the NMDA receptor/ion channel complex contains an integral ion channel that gates Na + , K + and Ca 2+ ions and is blocked in a voltage dependent manner by Mg 2+ . Excessive or abnormally prolonged stimulation of
- NMDA receptors leads to neuronal degeneration. Due to the structural arrangement of the NMDA receptor/channel, it is regulated at multiple sites. See Figure 1 .
- activity can be blocked by competitive antagonists, that is, molecules that interact at the same site as glutamate or aspartate but which do not activate the receptor.
- activity can be modulated by agents which block the ion channel, referred to as ion channel blockers .
- ion channel blockers agents which block the ion channel
- a number of other regulatory sites have been identified from which neurotransmitter activity can be modulated, including a receptor for glycine and two polyamine associated receptor sites, one of which lies within the ion channel.
- the present invention relates to the use of a specific group of compounds in the prevention and/or treatment of aminoglycoside- induced ototoxicity. These compounds are generally classified as functional NMDA antagonists since they reduce activity at NMDA receptors .
- Optytoxicity includes cochleotoxicity which results in hearing loss, and vestibulotoxicity, which results in loss of balance. Although many of the examples are directed to cochlear toxicity, one skilled in the art will clearly recognize that the present invention encompasses treatment and prevention of aminoglycoside-induced ototoxicity in the form of vestibulotoxicity.
- the functional NMDA antagonists of the present invention comprise compounds capable of acting on a number of different sites on the receptor ( Figure 1) .
- the antagonists of the present invention may act at a regulatory site known as the glycine binding site: examples include 7-chlorokynurenic acid, indole-2- carboxylic acid, L-687414, HA-966 and 1-aminocylopropane carboxylic acid (see Figure 5) .
- the compounds may act at the glutamate binding site: examples include 2- (2-carboxypiperazin-4-yl) propyl-1-phosphonic acid ("CPP").
- the functional NMDA antagonists of the present invention may act at a polyamine associated binding site: examples include diethylenetriamine, ifenprodil, eliprodil, conantokin-G and arcaine .
- these compounds may act as ion channel blockers of the NMDA receptor: examples include 1- [1- (2- thienyl)cyclohexyl] -piperidine (“TCP”), (+) 5 -methyl-10 , 11- dihydro-5H-dibenzo [a, d] cyclohepten-5, 10-imine maleate ("MK-801" or "Dizocilpine”), phencyclidine (“PCP”), ketamine and memantine.
- a particularly preferred group of functional NMDA antagonists comprises non-quinoline compounds, including but not limited to dizocilpine and ifenprodil. 0
- the comparable efficacies of these antagonists which act at discrete sites on the NMDA receptor, indicates that aminoglycoside antibiotics damage vulnerable cochlear neurons through an excitotoxic process requiring NMDA receptor activation. Both their specificity and the 5 modest dose range (approximately 1-20 mg/kg/day) required to limit aminoglycoside-induced hearing loss make these compounds ideal in its prevention and/or amelioration.
- Ototoxicity limits the clinical usefulness of aminoglycoside antibiotics.
- the present invention indicates that concurrent administration of functional NMDA antagonists in humans can attenuate aminoglycoside- 0 induced ototoxic damage.
- many functional NMDA antagonists are highly charged and have limited access to the central nervous system. Since access to the cochlea is not limited by the blood brain barrier, such agents may limit aminoglycoside- induced damage to cochlear neurons 5 and be devoid of any behavioral ' side effects.
- the schedule by which functional NMDA antagonists can be administered to prevent or ameliorate aminoglycoside- induced ototoxicity in humans will vary somewhat according to the circumstances and is within the 0 skill of the health care provider to determine. In many circumstances, it will be desirable to administer the functional NMDA antagonists concurrently with the aminoglycoside antibiotic. If the patient has already commenced aminoglycoside therapy, functional NMDA « - antagonists can be administered to ameliorate the ° ototoxicity which might otherwise occur. If aminoglycoside administration is contemplated, treatment with one or more functional NMDA antagonists can be commenced before the administration of the aminoglycoside, and continued during administration of the aminoglycoside.
- aminoglycosides were used to irrigate the peritoneal cavity during abdominal surgery.
- the present invention may permit restoration of this practice, which was discontinued largely due to ototoxicity.
- Efficacious amounts of a functional NMDA antagonist to be used in the method of the instant invention may be varied over a wide range.
- the typical c range of the amount of a functional NMDA antagonist compound is between about 0.5 mg/day and 800 mg/day.
- the efficacious amount and concentration of the compound to be administered are those which result in the composition exhibiting a reduction or prevention of aminoglycoside-induced ototoxicity.
- Our results suggest that the amount of functional NMDA antagonists that provide substantial protection against hypoxic/ischemic insults (e.g., in models of rodent middle cerebral artery occlusion) also are sufficient to prevent aminoglycoside- induced ototoxicity.
- Physicians and other practitioners skilled in the art are familiar with standard techniques for determining appropriate dosages in individual patients, (See, e . g. reference 21) .
- preferred amounts depend upon the rate of delivery of the active ingredient and the number of administrations which are used. Preferred amounts for any specific dose can be determined by normal pharmacological screening methods used in the art .
- the actual dosage amount administered can be determined by physical and physiological factors such as body weight, severity of condition, and idiopathy of the patient.
- Carrier materials for the pharmaceutical preparations of the present invention are well known in the pharmaceutical formulations art and include those carriers referred to as diluents or vehicles.
- the pharmaceutical compounds of the present invention can be administered orally, topically (for example, in the form of patches) , or parenterally, in a vehicle comprising one or more pharmaceutically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compounds, the chosen route of administration and standard biological practice.
- the compounds can be formulated in unit dosage forms such as capsules or tablets each containing a predetermined amount of active ingredient, ranging from about 0.5 mg to 800 mg, in a ° pharmaceutically acceptable carrier.
- the pharmaceutical composition of the present invention can take the form of a lyophilized powder of the active substance, to be dissolved immediately before use in a physiological solution for the purpose of injection.
- the compound is administered by either intravenous, subcutaneous or intramuscular injection, in compositions with pharmaceutically acceptable vehicles or carriers.
- parenteral administration it is preferred to use the 0 compound in solution in a sterile aqueous vehicle which may also contain other solutes such as buffers or preservatives as well as sufficient quantities of pharmaceutically acceptable salts or of glucose to make the solution isotonic.
- the pharmaceutical composition 5 according to the invention can also take a form which is suitable for oral administration.
- suitable forms are tablets, food gelatin capsules, dragees, powders and granules.
- the formulation of such oral forms is well- known to those skilled in the art. Any of the known 0 formulations are useful in preparing the instant oral pharmaceutical compositions.
- Suitable vehicles or carriers for the above noted formulations can be found in standard pharmaceutical texts, e.g. in "Remington's Pharmaceutical Sciences", 16th 5 ed. Mack Publishing Company, Eas-ton, Pa., 1980.
- the present invention also relates to a kit for screening aminoglycosides for potential ototoxicity.
- a kit for screening aminoglycosides for potential ototoxicity.
- One embodiment of such a kit comprises the following components: a source of NMDA receptor; a labeled ligand 0 that binds to sites inside the NMDA receptor coupled ion channel, such as dizocilpine or phencyclidine; a nonspecific binding molecule to estimate background binding levels; and a positive control.
- Many sources of NMDA receptor are known in the art. For example, rat brain - provides a rich source of NMDA receptors. It may be preferred to provide the NMDA receptor in a lyophilized form or in solution depending upon the format of the kit. Lyophilization may increase the shelf-life of the kit component.
- Labeled ligands may comprise any of the known and routinely used labels.
- commonly used labels include radioisotopes, biotin, fluorescent and chemiluminescent compounds, and luciferase.
- Other labels known to the skilled artisan are also encompassed herein.
- Molecules to be used for determining non-specific binding comprise unlabelled compounds such as phencyclidine, dizocilpine, ketamine and memantine .
- dizocilpine and phencyclidine are preferred molecules for determining the non-specific binding.
- Positive control molecules may include compounds that enhance the binding of labeled ligands and act at polyamine sites. Preferred examples are spermine and streptomycin.
- the third group consisted of guinea pigs receiving either dizocilpine maleate or ifenprodil tartrate (Research Biochemicals,
- Minipumps delivering 1 mg/kg of dizocilpine maleate per day in 40% DMSO/60% Milli-Q filtered water or 10 mg/kg ifenprodil tartrate per day in 40% DMSO/20% Emulphor/40% Milli-Q filtered water for 14 days were implanted subcutaneously under pentobarbital (25 mg/kg) and chloral hydrate (130 mg/kg) anesthesia.
- the fourth group consisted of guinea pigs receiving combinations of aminoglycosides and functional NMDA antagonists concurrently.
- the Preyer reflex consists of a flick or twitch of the pinnae (outer ear) in response to a tone of known frequency and intensity (17) .
- Guinea pigs were evaluated beginning 4 weeks after the initiation of drug regimens. Animals were immobilized in mesh restraining cages and placed inside a sound attenuated chamber (18x12x12 in) facing a 3 in diameter speaker located 4 in from the subject. The speaker was connected to a signal generator with variable signal attenuator, a variable frequency narrow bandpass 10 dB/octave Butterworth filter, a pulse timing unit, and a 10 watt audio amplifier. The sound intensity of the speaker output at 4 in.
- the stimulus tones consisted of a 300 msec long square-wave pulse (at 5,7, or 10 kHz) given once per second for five seconds.
- the number of ear flicks per stimulus train of 5 tones was recorded as the "percent response" (e.g. 3 ear flicks per train of 5 stimuli is a 60% response) .
- the tone stimulus train was then repeated at a higher sound intensity until either the maximum response rate (100%) was achieved or the maximum sound output at that frequency attained.
- Sigmoidal curves were fitted to the data via non-linear regression techniques for determination of the ER 50 and E ⁇ values.
- Guinea pigs respond to intense 5-10 kHz tones with a pinna flick referred to as the Preyer Reflex (13) .
- the presence of a Preyer reflex is dependent upon the sound pressure level (SPL) and the audibility magnitude to the animal.
- SPL sound pressure level
- 87+1.1, 72+0.9 and 75 ⁇ 0.9 dB are required to effect a 50% response rate (ER 50 ) to trains of 5, 7 and 10 kHz tones, respectively (Tables 1, la, Figure 2) , while a 100% response rate is obtained with 5-10 kHz tones of -100 dB SPL ( Figure 2) .
- ER 50 values in response to 5 kHz tones were not significantly different (99 to 109% of control) from saline-treated animals when these antibiotics were administered together with either NMDA antagonist (Tables 1, la, Figure 2) .
- Small (14-35%) increases in ER 50 values in response to 7 and 10 kHz tones were observed in animals treated with combinations of these antibiotics and NMDA antagonists.
- concurrent administration of NMDA antagonists restored the maximum response rates in antibiotic-treated animals to values approaching 100% (Tables 1, la, Figure 2) .
- Neomycin > 120** > 120** > 120**
- Ifenprodil + Kanamycin 100 ⁇ 0 lOO ⁇ O 100 ⁇ 0 The Preyer reflex was measured in male Hartley guinea pigs beginning 4 weeks after initiating ototoxic regimens of neomycin and kanamycin as described above.
- the ED 50 is that sound pressure level eliciting a 50% response (pinnae flick) rate. Values represent the mean + SEM of observations from 4 - 25 animals. *, **: Significantly different from the saline group, P ⁇ 0.05, 0.01, respectively, ANOVA followed by Tukey's post-hoc multiple comparison test. All other groups were significantly different from either the neomycin or kanamycin only groups, P ⁇ 0.01.
- Example 1 Male, albino Hartley guinea pigs (250-300 g, Charles Rivers, Raleigh, NC) were maintained under similar conditions, and received the same drug treatments as described in Example 1.
- DPOE distortion product otoacoustic emissions
- guinea pigs were anesthetized (ketamine 40 mg/kg and xylazine 4 mg/kg) and a CUBDISPTM system (consisting of microphones and high fidelity earphones (Etymotic Research, Oak Grove Village, IL) placed in each ear.
- Pairs of continuous tones (65 and 50 dB SPL for fl and f2, respectively) ranging from 1-16 kHz were presented in descending sequences.
- the 2fl-f2 DPOE together with associated background noise were recorded by the CUBDISPTM system and plotted as a function of stimulus frequency.
- the DPOE recorded from saline-treated guinea pigs were characteristic of intact cochleae (24) ( Figure 3) .
- Concurrent administration of NMDA antagonists increased DPOE amplitudes well above the noise floor ( Figure 3) to values approaching those obtained in control subjects.
- NMDA Receptor antagonists attenuate aminoglycoside-induced hearing loss: Effects on DPOE amplitude.
- Neomycin 16 0 0 16**
- DPOE Distortion product otoacoustic emissions
- mice Male, albino Hartley guinea pigs (250-300 g, Charles River, Raleigh, NC) were maintained under similar conditions, and received the same drug treatments as described in Example 1. 5 After DPOE measurements, some guinea pigs were euthanized with an overdose of chloral hydrate anesthesia. Guinea pigs treated with saline, neomycin, neomycin + dizocilpine, and neomycin + ifenprodil (2 animals/group) were then transcardially perfused with Tyrode's solution 0 followed by mixed aldehydes (2% paraformaldehyde, 2.5% glutaraldehyde) in cacodylate buffer, pH 7.2.
- mixed aldehydes 2% paraformaldehyde, 2.5% glutaraldehyde
- the cochleas were removed, fixed overnight in the mixed aldehyde solution, washed and decalcified in 8% EDTA for two weeks . They were then dehydrated and embedded in 5 glycol methacrylate . Using a microtome, serial 4 ⁇ m ' ⁇ sections were cut in the plane of the modiolus ; every 8th section was mounted on a glass slide and stained with toluidine blue prior to coverslipping.
- mice Male, Sprague-Dawley rats (200-300 g, Taconic Farms, Germantown, NY) provided the brain tissue used for the radioligand binding assays. These animals were maintained under similar conditions as described in Example 1 for guinea pigs, but in separate facilities.
- Rat cerebral cortex was homogenized in preparation buffers (15,16) with a Polytron (Brinkmann Instruments, Westbury, New York) and extensively "washed” (resuspended and recentrifuged) to remove endogenous materials (e.g. glycine, glutamate, polyamines) that affect radioligand binding to NMDA receptors. Extensively washed membranes were suspended in 5-10 volumes (original wet weight) of 5 mM HEPES/4.5 mM- Tris (HTS) buffer (pH 7.4) at stored at -70°.
- preparation buffers 15,16
- Polytron Warner Instruments, Westbury, New York
- endogenous materials e.g. glycine, glutamate, polyamines
- Extensively washed membranes were suspended in 5-10 volumes (original wet weight) of 5 mM HEPES/4.5 mM- Tris (HTS) buffer (pH 7.4) at stored at -70°.
- [ 3 H] Dizocilpine binding Forebrain homogenates were thawed, diluted to a concentration of 1:50 with HTS, and washed twice. After the final centrifugation step, the pellet was resuspended in 25 vol of HTS. Assays were performed in duplicate using 1.5 ml plastic microtiter plates and consisted of 50 ⁇ l of aminoglycoside or spermine (1-3000 ⁇ M) , 300 ⁇ l of tissue suspension, 50 ⁇ l [ 3 H] dizocilpine (final concentration, 3.5 nM) , and HTS buffer to a volume of 500 ⁇ l . Nonspecific binding was determined using dizocilpine (10 ⁇ M) .
- Incubations were conducted at room temperature and terminated after 2 hours by rapid filtration over Schleicher and Schuell #32 filters (Keene, NH) pretreated with 0.03% polyethylenimine . Filters were rapidly washed with 2 x 2.5 ml of ice cold HTS.
- Duplicate tubes contained: 50 ⁇ l of aminoglycoside (0.1 - 1000 ⁇ M) , 50 ⁇ l membrane suspension, 50 ⁇ l (+) -pentazocine (10 ⁇ M, to block ⁇ sites), 50 ⁇ l of [ 3 H] ifenprodil (5 nM) and HTS buffer to a final volume of 500 ⁇ l .
- Non-specific binding '" was determined using 10 ⁇ M ifenprodil .
- the assay was incubated at 4°C for 2 hours and terminated by rapid filtration over S+S #32 filters pretreated with 0.03% polyethylenimine. Filters were washed with 2 x 2.5 ml of ice-cold HTS. All binding data were analyzed by nonlinear regression.
- Endogenous polyamines such as spermine initially enhance, and at higher concentrations inhibit [ 3 H] dizocilpine binding (29, 30) .
- Endogenous polyamines such as spermine initially enhance, and at higher concentrations inhibit [ 3 H] dizocilpine binding (29, 30) .
- EC 50 values are the aminoglycoside concentrations that increase [ 3 H] dizocilpine (3.5 nM) binding to rat forebrain homogenates by 50% of maximum.
- E, ⁇ is the maximal enhancement of [ 3 H] dizocilpine binding expressed as the % increase above basal (non-stimulated) values .
- IC 50 values are presented for those aminoglycosides exhibiting a biphasic effect on [ 3 H] dizocilpine binding.
- NMDA antagonists are tested in humans being treated with the aminoglycosides neomycin, gentamycin and kanamycin.
- Patients are treated with 1-3 mg/kg gentamycin 3 times daily for the duration of an infection; 500-2000 mg neomycin 4 times daily for a period of 4 days; or 5-7.5 mg/kg amikacin every 8-12 hr. for the duration of the infection.
- the functional NMDA antagonists used in combination with these aminoglycosides include at least one of ifenprodil, memantine or dizocilpine.
- EXAMPLE 6 The functional NMDA antagonists, dizocilpine and ifenprodil are administered to patients at dosages of 0.1 mg/kg/day and 2 mg/kg/day respectively prior to beginning aminoglycoside treatment. The bacterial infection is cured and the subject suffers no ototoxic damage.
- Neomycin is an agonist at a polyamine site on the N-methyl-D-asparate receptor. J " .
- N-methyl-D-aspartate receptor pharmacological evidence for the existence of a polyamine recognition site. Mol . Pharm . 36, 575-581, (1989) .
Abstract
The present invention relates to functional NMDA antagonists and their ability to ameliorate aminoglycoside induced ototoxicity. These compositions are useful in the treatment or prevention of such hearing loss and/or loss of balance. A pharmaceutical composition comprising an aminoglycoside and at least one functional NMDA receptor antagonist administered simultaneously provides bacteriocidal activity and protection from aminoglycoside-induced ototoxicity.
Description
THE USE OF FUNCTIONAL N-METHYL-D-ASPARTATE ANTAGONISTS TO AMELIORATE OR PREVENT AMINOGLYCOSIDE- INDUCED OTOTOXICITY
SCOPE OF THE PRESENT INVENTION
The present invention relates to the use of a class of compounds to ameliorate and prevent aminoglycoside-induced ototoxicity. These compounds fall within the group of substances which reduce activity at N- methyl-D-aspartate (NMDA) receptors and are referred to as functional NMDA antagonists.
BACKGROUND
Aminoglycoside antibiotics are polycations consisting of amino sugars connected to an aminocyclitol nucleus, and are derived from the fungi Strep tomyces and Micromonospora (1,2). Aminoglycoside antibiotics potently inhibit protein synthesis at the ribosomal level and compromise membrane integrity in a range of Gram-negative and some Gram-positive bacteria. These agents are clinically valued for their rapid onset of bacteriocidal activity, synergism with β-lactam antibiotics and low cost. They are commonly used to treat Gram-negative sepsis, endocarditis, nosocomial infections and tuberculosis .
While aminoglycosides are administered each year to approximately 3% of all clinical admissions in the United States (3), a major drawback to their use is serious ototoxicity (4) . This ototoxicity results from the gradual destruction of sensory hair cells starting in the basal turns then ascending to the apex of the cochlea. The rapidity and degree of hearing loss in patients receiving aminoglycosides is dose-dependent and usually permanent. Moreover, measurable signs of hearing loss are found in approximately 20-33% of the patients receiving aminoglycoside antibiotics despite dosage limits and blood level monitoring (5) .
Despite the widespread occurrence of
° aminoglycoside-induced hearing impairments, the molecular mechanism (s) underlying this ototoxicity remain unknown. Aminoglycoside-induced ototoxicity has been ascribed to the inhibition of RNA synthesis (6) , blockade of calcium- dependent potassium channels (7) , and the inhibition of 5 phosphoinositide metabolism (8) in cochlear hair cells. However, additional studies indicate that other cells in the cochlea may take up aminoglycosides without permanent toxic effects (7) .
Recently, reports have been made of the presence
10 of NMDA receptor mRNA in the synapses between cochlear hair cells and spiral ganglion neurons (9, 10) , and of the enhancement of radioligand binding to the NMDA receptor by aminoglycosides in a polyamine-like fashion (11) . It is also known that there are a number of isoforms of NMDA
15 receptors, some of which are not responsive to polyamines. ' The reports on NMDA receptor mRNA did not discriminate among receptor isoforms, and, therefore, whether the isoforms in the tissues tested were sensitive or insensitive to polyamines. Moreover, since not all NMDA
20 receptor isoforms exhibit potentiation by polyamines (22) , it was not known on the basis of these reports whether any of the NMDA receptors present in cochlear hair cells would respond to polyamines or to compounds which mimic polyamines, such as aminoglycosides.
2« One object of the invention relates to the prevention and/or amelioration of aminoglycoside induced ototoxicity by use of NMDA antagonists.
Another object of the invention relates to the use of functional NMDA antagonists to provide substantial protection against aminoglycoside- induced ototoxicity in a patient .
A further object of the invention relates to the use of NMDA antagonists as a pharmaceutical composition in the prevention or amelioration of aminoglycoside induced
~_ ototoxicity.
Yet another object of the invention is to provide an improved method of antibiotic treatment to prevent aminoglycoside-induced ototoxicity comprising the step of administering a therapeutically effective amount of a NMDA antagonist in combination with an aminoglycoside antibiotic .
An additional object of the invention relates to a bacteriocidal antibiotic composition comprising a therapeutically effective amount of an aminoglycoside and functional NMDA antagonists to control ototoxicity.
10
SUMMARY OF THE INVENTION
The aminoglycoside antibiotics are bacteriocidal agents whose clinical utility is limited by their ototoxicity. This ototoxicity can result in significant 5 hearing loss and/or a loss of balance. Recently, NMDA receptors were identified at the cochlear hair cell-spiral ganglion neuron synapse. Further, a recent in vi tro study demonstrated the ability of aminoglycosides to modulate NMDA receptor function via the polyamine site. The
20 present invention relates to the discovery that enhancement of glutamatergic neurotransmission at the hair cell synapse by aminoglycosides results in necrosis of either the hair cells and/or spiral ganglion neurons through excitotoxic mechanisms (12) which could be
25 amenable to intervention with functional NMDA antagonists.
Accordingly, the present invention relates to the identification of functional NMDA antagonists, which are capable of ameliorating or preventing aminoglycoside- induced hearing loss or loss of balance. These o antagonists act at a variety of sites on NMDA receptors including, but not limited to, the polyamine binding site, the ion channel, the glycine binding site and the glutamate binding site. The effect of these functional NMDA antagonists is to reduce the activity of NMDA o<- receptors. Preferred compounds of the present invention
comprise quinoline and non-quinoline functional NMDA antagonists . The more preferred compounds are non- quinolines .
The compounds of the present invention are useful as a pharmaceutical composition either alone in the amelioration or prevention of aminoglycoside- induced ototoxicity, (as in the treatment of patients receiving aminoglycosides) , or in combination with an aminoglycoside in order to prevent ototoxicity and simultaneously provide bacteriocidal activity. The present invention demonstrates that concurrent administration of functional NMDA antagonists and aminoglycosides limits cochlear damage, vestibular damage and hearing impairment produced by aminoglycoside antibiotics. Methods of using such pharmaceutical compounds in treating aminoglycoside- induced ototoxicity are also provided. These methods include an improved method of aminoglycoside antibiotic treatment which prevents aminoglycoside-induced ototoxicity.
In addition, the ability of aminoglycosides to modulate ligand binding to NMDA receptors also provides an effective screen for developing new aminoglycoside antibiotics with reduced ototoxic potential.
BRIEF DESCRIPTION OF THE DRAWINGS Embodiments of the present invention are described by way of example with reference to the accompanying figures :
Figure 1. Schematic diagram of the NMDA receptor complex. The NMDA receptor complex is composed of several protein subunits clustered in such a way as to form a channel, which, when opened, is permeable to sodium and calcium ions. Excessive entry of calcium ions into a hair cell or neuron can result in the death of that cell . Surrounding and within the channel are numerous modulatory sites, including recognition sites for: glutamate;
° glycine; multiple polyamine associated sites (one within the ion channel) ; and the dizocilpine (or MK-801) binding site within the ion channel .
Figure 2. NMDA antagonists limit neomycin- induced decrements in the Preyer reflex response to 5 (Panel A), 7 (Panel B) , and 10 (Panel C) kHz tones. The
Preyer reflex is a measure of hearing threshold well known in the art (17, 18) . Two groups of guinea pigs received daily subcutaneous injections of either saline (•) or neomycin (O) for 14 days. Two other groups of guinea pigs received subcutaneous injections of neomycin together with either dizocilpine (1 mg/kg/d, ■) or ifenprodil (10 mg/kg/d, A) delivered by subcutaneous osmotic minipumps . The Preyer reflex was examined in these animals 2 weeks after completing the antibiotic regimen. At the maximum sound pressure level (120 dB) used in these studies, ' neomycin reduced the maximal response rates to <15% at all three frequencies, precluding an accurate estimate of the 50% response rate (ER50) . While dizocilpine and ifenprodil restored the maximal response rates in neomycin-treated animals to values indistinguishable from controls, modest but statistically significant increases in ER50 values were present at 7 and 10 kHz. In the absence of antibiotics, dizocilpine and ifenprodil treatment did not affect either the maximal response rates or ER50 values. Figure 3. NMDA antagonists limit neomycin- induced reductions in distortion product otoacoustic emissions (DPOE) . Each ear of each animal subject was tested; data points represent the mean DPOE amplitude determined from 12-20 ears. The DPOE from saline-treated animals (O, n= 12 ears) is presented for comparison
(Panels A-D) . Panels A and B: Chronic administration of neomycin (D, n= 16 ears) reduced DPOE amplitudes to values within + 1 S.D. of the noise floor (dashed lines), indicating a complete loss of hearing over the range of 0.5-16 kHz. (The "noise floor" is a sound level below
° that which can be detected by the measuring device at a particular frequency. Values at the noise floor for a frequency are recognized as indicating total hearing loss at that frequency.) Concurrent treatment with neomycin and dizocilpine (Panel A, •, n = 20 ears) or ifenprodil 5 (Panel B, A, n = 20 ears) maintained DPOE amplitudes above the noise floor, with a slight decrease in DPOE amplitude between 11500 and 16000 Hz. Panels C and D: Chronic administration of kanamycin (Δ, n = 16 ears) also induced severe cochlear damage, as indicated by the reduction of 0 DPOE amplitudes to within ± 1 S.D. of the noise floor. However, concurrent administration of kanamycin with dizocilpine (Panel C, •, n = 20 ears) or ifenprodil (Panel D, A, n = 20 ears) maintained DPOE amplitudes above the noise floor, with moderate reductions in DPOE amplitude, 5 particularly between 2500 and 6500 Hz. In >90% of the animals tested, the audiograms were qualitatively similar in both ears .
Figure 4. A summary of the changes in inner (A) and outer (B) hair cell populations of cochleae from 0 individual guinea pigs treated with neomycin (■) , neomycin + dizocilpine (•) , or neomycin + ifenprodil (A) in serial sections cut through the organ of Corti. Results are expressed as the percentage of cells missing compared to normal guinea pig cochleae. Note the total loss of both 5 inner and outer hair cells between 13 to 18 mm from the apex of the cochlea in the neomycin treated guinea pig. Treatment of guinea pigs with either dizocilpine or ifenprodil resulted in complete protection against hair cell loss between 13 to 17 mm from the apex. 0 Figure 5. Effect of aminoglycosides on [3H] dizocilpine binding to NMDA receptors: relationship to ototoxicity. A) Enhancement of [3H] dizocilpine binding by representative aminoglycosides: streptomycin (O) , amikacin (■) , and spectinomycin (•) . The biphasic _- modulation of [3H] dizocilpine binding by streptomycin is
similar to that of the polyamine, spermine. B) The potencies of a series of ototoxic aminoglycosides in enhancing [3H] dizocilpine binding is highly (Bonferroni corrected Pearson correlation coefficient = 0.928, P<0.01) correlated with their relative ototoxicities in humans (2) . There was no significant correlation between the E,^ and the relative aminoglycoside ototoxicity (Bonferroni corrected Pearson correlation coefficient = 0.046, P=0.83). Spectinomycin is not included in this correlation because it is not ototoxic. Streptomycin lies well outside this correlation. The anomalous behavior of streptomycin may be related to an open channel block (corresponding to the inhibition of [3H] dizocilpine binding, panel A) , which would limit its ototoxicity. Figure 6. Chemical structures for some functional NMDA antagonists.
DETAILED DESCRIPTION OF THE INVENTION
The NMDA receptor is one of the major subtypes of fast excitatory neurotransmitter receptors in the mammalian central nervous system. These receptors are activated by the acidic amino acids glutamate and aspartate . The NMDA receptor/ion channel complex contains an integral ion channel that gates Na+, K+ and Ca2+ ions and is blocked in a voltage dependent manner by Mg2+ . Excessive or abnormally prolonged stimulation of
NMDA receptors leads to neuronal degeneration. Due to the structural arrangement of the NMDA receptor/channel, it is regulated at multiple sites. See Figure 1 . First, activity can be blocked by competitive antagonists, that is, molecules that interact at the same site as glutamate or aspartate but which do not activate the receptor. Second, activity can be modulated by agents which block the ion channel, referred to as ion channel blockers . Third, a number of other regulatory sites have been identified from which neurotransmitter activity can be
modulated, including a receptor for glycine and two polyamine associated receptor sites, one of which lies within the ion channel. The present invention relates to the use of a specific group of compounds in the prevention and/or treatment of aminoglycoside- induced ototoxicity. These compounds are generally classified as functional NMDA antagonists since they reduce activity at NMDA receptors .
"Ototoxicity", as the term is used herein, includes cochleotoxicity which results in hearing loss, and vestibulotoxicity, which results in loss of balance. Although many of the examples are directed to cochlear toxicity, one skilled in the art will clearly recognize that the present invention encompasses treatment and prevention of aminoglycoside-induced ototoxicity in the form of vestibulotoxicity.
The functional NMDA antagonists of the present invention comprise compounds capable of acting on a number of different sites on the receptor (Figure 1) . The antagonists of the present invention may act at a regulatory site known as the glycine binding site: examples include 7-chlorokynurenic acid, indole-2- carboxylic acid, L-687414, HA-966 and 1-aminocylopropane carboxylic acid (see Figure 5) . Alternatively, the compounds may act at the glutamate binding site: examples include 2- (2-carboxypiperazin-4-yl) propyl-1-phosphonic acid ("CPP"). Further, the functional NMDA antagonists of the present invention may act at a polyamine associated binding site: examples include diethylenetriamine, ifenprodil, eliprodil, conantokin-G and arcaine . In addition, these compounds may act as ion channel blockers of the NMDA receptor: examples include 1- [1- (2- thienyl)cyclohexyl] -piperidine ("TCP"), (+) 5 -methyl-10 , 11- dihydro-5H-dibenzo [a, d] cyclohepten-5, 10-imine maleate ("MK-801" or "Dizocilpine"), phencyclidine ("PCP"), ketamine and memantine. These compounds and several other
° functional NMDA antagonists are illustrated in Figure 6. Both quinoline and non-quinoline compounds can be used in the present method as long as they act as functional NMDA antagonists. Both in vi tro and in vivo tests for determining whether a given compound is a 5 functional NMDA antagonist are well known in the art. ( See, e . g. references 12, 16, 19 and 20) .
A particularly preferred group of functional NMDA antagonists comprises non-quinoline compounds, including but not limited to dizocilpine and ifenprodil. 0 The comparable efficacies of these antagonists, which act at discrete sites on the NMDA receptor, indicates that aminoglycoside antibiotics damage vulnerable cochlear neurons through an excitotoxic process requiring NMDA receptor activation. Both their specificity and the 5 modest dose range (approximately 1-20 mg/kg/day) required to limit aminoglycoside-induced hearing loss make these compounds ideal in its prevention and/or amelioration.
Four significant observations based on auditory, histological and pharmacological studies in guinea pigs 0 provide concrete evidence for the use of functional NMDA antagonists in the amelioration of aminoglycoside-induced ototoxicity, and constitute the basis for a new screening assay to evaluate the ototoxic potential of new aminoglycosides. First, functional NMDA antagonists 5 substantially ameliorate the aminoglycoside-induced loss of the Preyer reflex, a response indicative of the animals auditory threshold (Figure 2) . Second, co-administration of functional NMDA antagonists substantially reduce the aminoglycoside- induced loss of the ability of guinea pigs 0 to hear tones ranging from 500 to 16,500 cycles per second (Hz) (Figure 3) . Third, administration of functional NMDA antagonists almost completely eliminates the aminoglycoside-induced destruction of inner and outer cochlear hair cells which underlies the loss of hearing <r sensitivity to 500-16,500 Hz tones (Figure 4). Fourth,
° the potency of a series of aminoglycosides in enhancing the binding of [3H] dizocilpine is significantly correlated with the ototoxic potential of these compounds (Figure 5) . Moreover, the potency of aminoglycosides in enhancing [3H] dizocilpine binding is within the range of ototoxic 5 concentrations of these compounds in the cochlear perilymph (3) . The ability of aminoglycosides to enhance the binding of ligands to the NMDA receptor complex at pathophysiologically relevant doses provides a solid mechanism to explain the ototoxic properties of these 0 antibiotics. Also, this data provides a rational explanation for the use of functional NMDA antagonists in preventing and/or ameliorating the ototoxicity of aminoglycosides and constitutes an assay by which potential aminoglycoside antibiotics may be screened for 5 their ototoxic liability (See examples 1-4) .
Ototoxicity limits the clinical usefulness of aminoglycoside antibiotics. The present invention indicates that concurrent administration of functional NMDA antagonists in humans can attenuate aminoglycoside- 0 induced ototoxic damage. Moreover, many functional NMDA antagonists are highly charged and have limited access to the central nervous system. Since access to the cochlea is not limited by the blood brain barrier, such agents may limit aminoglycoside- induced damage to cochlear neurons 5 and be devoid of any behavioral ' side effects.
The schedule by which functional NMDA antagonists can be administered to prevent or ameliorate aminoglycoside- induced ototoxicity in humans will vary somewhat according to the circumstances and is within the 0 skill of the health care provider to determine. In many circumstances, it will be desirable to administer the functional NMDA antagonists concurrently with the aminoglycoside antibiotic. If the patient has already commenced aminoglycoside therapy, functional NMDA «- antagonists can be administered to ameliorate the
° ototoxicity which might otherwise occur. If aminoglycoside administration is contemplated, treatment with one or more functional NMDA antagonists can be commenced before the administration of the aminoglycoside, and continued during administration of the aminoglycoside. 5 While the practitioner may choose to cease administration of the functional NMDA antagonist or antagonists at or around the time of cessation of aminoglycoside administration, it will often be desirable to continue administration of the functional NMDA antagonist or 0 antagonists for up to a month thereafter. This is so first, because the clearance of aminoglycosides from the body takes a substantial period of time and, second, because glutamate induced cell death continues for a time even after aminoglycoside administration ends. It is 5 within the skill of the practitioner to determine how long to administer the functional NMDA antagonist or antagonists after cessation of aminoglycoside therapy based on the known pharmacokinetics of the particular aminoglycoside the practitioner has chosen to employ and 0 the pharmacodynamics of the particular functional NMDA antagonists used. The functional NMDA antagonists could be used in conjunction with any aminoglycoside drug, or as a combination pharmaceutical preparation
It is contemplated that the ability to prevent 5 or limit aminoglycoside-induced ototoxicity could result both in more frequent administration and in broader use of aminoglycosides. In the past, for example, aminoglycosides were used to irrigate the peritoneal cavity during abdominal surgery. The present invention may permit restoration of this practice, which was discontinued largely due to ototoxicity.
Efficacious amounts of a functional NMDA antagonist to be used in the method of the instant invention may be varied over a wide range. The typical c range of the amount of a functional NMDA antagonist
compound is between about 0.5 mg/day and 800 mg/day. Generally, the efficacious amount and concentration of the compound to be administered are those which result in the composition exhibiting a reduction or prevention of aminoglycoside-induced ototoxicity. Our results suggest that the amount of functional NMDA antagonists that provide substantial protection against hypoxic/ischemic insults (e.g., in models of rodent middle cerebral artery occlusion) also are sufficient to prevent aminoglycoside- induced ototoxicity. Physicians and other practitioners skilled in the art are familiar with standard techniques for determining appropriate dosages in individual patients, (See, e . g. reference 21) . In addition, preferred amounts depend upon the rate of delivery of the active ingredient and the number of administrations which are used. Preferred amounts for any specific dose can be determined by normal pharmacological screening methods used in the art . The actual dosage amount administered can be determined by physical and physiological factors such as body weight, severity of condition, and idiopathy of the patient.
Carrier materials for the pharmaceutical preparations of the present invention are well known in the pharmaceutical formulations art and include those carriers referred to as diluents or vehicles. The pharmaceutical compounds of the present invention can be administered orally, topically (for example, in the form of patches) , or parenterally, in a vehicle comprising one or more pharmaceutically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compounds, the chosen route of administration and standard biological practice. For oral administration, the compounds can be formulated in unit dosage forms such as capsules or tablets each containing a predetermined amount of active ingredient, ranging from about 0.5 mg to 800 mg, in a
° pharmaceutically acceptable carrier.
The pharmaceutical composition of the present invention can take the form of a lyophilized powder of the active substance, to be dissolved immediately before use in a physiological solution for the purpose of injection. 5 For parenteral administration, the compound is administered by either intravenous, subcutaneous or intramuscular injection, in compositions with pharmaceutically acceptable vehicles or carriers. For administration by injection, it is preferred to use the 0 compound in solution in a sterile aqueous vehicle which may also contain other solutes such as buffers or preservatives as well as sufficient quantities of pharmaceutically acceptable salts or of glucose to make the solution isotonic. The pharmaceutical composition 5 according to the invention can also take a form which is suitable for oral administration. For example, suitable forms are tablets, food gelatin capsules, dragees, powders and granules. The formulation of such oral forms is well- known to those skilled in the art. Any of the known 0 formulations are useful in preparing the instant oral pharmaceutical compositions.
Suitable vehicles or carriers for the above noted formulations can be found in standard pharmaceutical texts, e.g. in "Remington's Pharmaceutical Sciences", 16th 5 ed. Mack Publishing Company, Eas-ton, Pa., 1980.
The present invention also relates to a kit for screening aminoglycosides for potential ototoxicity. One embodiment of such a kit comprises the following components: a source of NMDA receptor; a labeled ligand 0 that binds to sites inside the NMDA receptor coupled ion channel, such as dizocilpine or phencyclidine; a nonspecific binding molecule to estimate background binding levels; and a positive control. Many sources of NMDA receptor are known in the art. For example, rat brain - provides a rich source of NMDA receptors. It may be
preferred to provide the NMDA receptor in a lyophilized form or in solution depending upon the format of the kit. Lyophilization may increase the shelf-life of the kit component. Labeled ligands may comprise any of the known and routinely used labels. For example, commonly used labels include radioisotopes, biotin, fluorescent and chemiluminescent compounds, and luciferase. Other labels known to the skilled artisan are also encompassed herein. Molecules to be used for determining non-specific binding comprise unlabelled compounds such as phencyclidine, dizocilpine, ketamine and memantine . For example, dizocilpine and phencyclidine are preferred molecules for determining the non-specific binding. Positive control molecules may include compounds that enhance the binding of labeled ligands and act at polyamine sites. Preferred examples are spermine and streptomycin. All publications, patents and articles referred to herein are expressly incorporated herein in toto by reference thereto. The following examples are presented to illustrate the present invention but are in no way to be construed as limitations on the scope of the invention. It will be recognized by those skilled in the art that numerous changes and substitutions may be made without departing from the spirit and purview of the invention.
EXAMPLE 1
Studies of the Preyer Reflex were performed in albino male Hartley guinea pigs (250-200 g each, Charles River) . The guinea pigs were maintained in AAALAC- accredited facilities which included a 12 hour day/night cycle (lights on at 0700) and free access to food and water. The animals were divided into 4 major groups. The normal control group of guinea pigs was administered a daily subcutaneous injection of physiological saline (1 ml) for 14 or 21 consecutive days. Aminoglycoside ototoxicity was induced by the administration of either
neomycin sulfate(13) (Sigma Chemicals, St. Louis MO, 150 mg/kg/D in 1 ml, subcutaneous (SC) , for 14 days) or kanamycin sulfate (Sigma Chemicals, St. Louis MO, 250 mg/kg/D in ml, SC, for 21 days) (14) . The third group consisted of guinea pigs receiving either dizocilpine maleate or ifenprodil tartrate (Research Biochemicals,
Inc., Natick, MA) by subcutaneous osmotic minipumps (Alzet 200, Alza Scientific Instruments, Palo Alto, CA) . Minipumps delivering 1 mg/kg of dizocilpine maleate per day in 40% DMSO/60% Milli-Q filtered water or 10 mg/kg ifenprodil tartrate per day in 40% DMSO/20% Emulphor/40% Milli-Q filtered water for 14 days were implanted subcutaneously under pentobarbital (25 mg/kg) and chloral hydrate (130 mg/kg) anesthesia. The fourth group consisted of guinea pigs receiving combinations of aminoglycosides and functional NMDA antagonists concurrently. At the end of 14 days, the depleted minipumps were surgically removed and a fresh pump implanted for another 14 day delivery schedule. Auditory testing of these guinea pigs began 4 weeks after initiating the drug or saline treatments. Measurement of Hearing Threshold
The Preyer reflex consists of a flick or twitch of the pinnae (outer ear) in response to a tone of known frequency and intensity (17) . Guinea pigs were evaluated beginning 4 weeks after the initiation of drug regimens. Animals were immobilized in mesh restraining cages and placed inside a sound attenuated chamber (18x12x12 in) facing a 3 in diameter speaker located 4 in from the subject. The speaker was connected to a signal generator with variable signal attenuator, a variable frequency narrow bandpass 10 dB/octave Butterworth filter, a pulse timing unit, and a 10 watt audio amplifier. The sound intensity of the speaker output at 4 in. was determined for each frequency using a calibrated microphone, and ranged from 50-120 dB SPL at 5 kHz to 50-105 dB SPL at 7
and 10 kHz, respectively. The stimulus tones consisted of a 300 msec long square-wave pulse (at 5,7, or 10 kHz) given once per second for five seconds. The number of ear flicks per stimulus train of 5 tones was recorded as the "percent response" (e.g. 3 ear flicks per train of 5 stimuli is a 60% response) . The tone stimulus train was then repeated at a higher sound intensity until either the maximum response rate (100%) was achieved or the maximum sound output at that frequency attained. Sigmoidal curves were fitted to the data via non-linear regression techniques for determination of the ER50 and E^ values.
Dizocilpine and Ifenprodil Ameliorate Aminoglycoside- Induced Decrements in the Preyer Reflex.
Guinea pigs respond to intense 5-10 kHz tones with a pinna flick referred to as the Preyer Reflex (13) . The presence of a Preyer reflex is dependent upon the sound pressure level (SPL) and the audibility magnitude to the animal. In control animals, 87+1.1, 72+0.9 and 75±0.9 dB are required to effect a 50% response rate (ER50) to trains of 5, 7 and 10 kHz tones, respectively (Tables 1, la, Figure 2) , while a 100% response rate is obtained with 5-10 kHz tones of -100 dB SPL (Figure 2) . Following chronic administration of either neomycin or kanamycin, the sound pressures required to elicit a 50% response rate to 5 and 7 kHz tones exceeded levels which could be measured in our apparatus (>120 dB SPL) , with a response rate of < 20% obtained at 120 dB SPL. Antibiotic treated animals were completely unresponsive to 10 kHz tones at maximum sound pressure (120 dB SPL) (Fig 1, Table 1) . Concurrent administration of either dizocilpine (1 mg/kg/day) or ifenprodil (10 mg/kg/day) significantly attenuated both the neomycin and kanamycin- induced loss of the Preyer reflex (Tables 1,1a, Figure 2). The ER50 values in response to 5 kHz tones were not significantly different (99 to 109% of control) from saline-treated
animals when these antibiotics were administered together with either NMDA antagonist (Tables 1, la, Figure 2) . Small (14-35%) increases in ER50 values in response to 7 and 10 kHz tones were observed in animals treated with combinations of these antibiotics and NMDA antagonists. Despite these modest increases in ER50 values, concurrent administration of NMDA antagonists restored the maximum response rates in antibiotic-treated animals to values approaching 100% (Tables 1, la, Figure 2) .
Table 1 and Table la. Functional NMDA Antagonists Ameliorate Aminoglycoside
Induced Ototoxicity: the Preyer Reflex.
TABLE 1. Sound Pressure ED50 (dB)
Treatment 5 kHz 7 kHz 10 kHz
Saline 87± 1.1 72±0.9 75±0.9
Neomycin > 120** > 120** > 120**
Kanamycin > 120** > 120** > 120**
Dizocilpine 83± 1.3 75± 1.1 75± 1.0
Ifenprodil 84± 1.3 73± 1.0 74± 1.7
Dizocilpine + Neomycin 95±3.0 86±2.9** 86±2.9**
Dizocilpine + Kanamycin 95 ±4.1 97±4.8** 97±7.3**
Ifenprodil + Neomycin 86± 1.4 85±2.8* 85±4.5
Ifenprodil + Kanamycin 88± 1.4 82± 1.1* 80±2.4
TABLE la Maximal Response Rate
(%)
Treatment 5 kHz 7 kHz 10 kHz
Saline lOO±O 100 ±0 100 ±0
Neomycin 13±3.9** 14±9.8** O±O**
Kanamycin 13±8.4** 3.3±3.3** 6.7±4.2**
Dizocilpine lOO±O lOO±O lOO±O
Ifenprodil lOO±O lOO±O lOO±O
Dizocilpine + Neomycin 87±9.1 96±6.7 88±8.4
Dizocilpine + Kanamycin 77 ± 17 83 ± 17 67±21*
Ifenprodil + Neomycin lOO±O 98±2.2 90± 10
Ifenprodil + Kanamycin 100 ±0 lOO±O 100 ±0
The Preyer reflex was measured in male Hartley guinea pigs beginning 4 weeks after initiating ototoxic regimens of neomycin and kanamycin as described above. The ED50 is that sound pressure level eliciting a 50% response (pinnae flick) rate. Values represent the mean + SEM of observations from 4 - 25 animals. *, **: Significantly different from the saline group, P<0.05, 0.01, respectively, ANOVA followed by Tukey's post-hoc multiple comparison test. All other groups were significantly different from either the neomycin or kanamycin only groups, P<0.01.
EXAMPLE 2 Distortion Product Otoacoustic Emissions (DPOE)
Male, albino Hartley guinea pigs (250-300 g, Charles Rivers, Raleigh, NC) were maintained under similar conditions, and received the same drug treatments as described in Example 1.
Measurement of distortion product otoacoustic emissions (DPOE) is one of several non-invasive means of evaluating outer hair cell and general cochlear integrity along the organ of Corti (23) . The DPOE is most useful in determining alterations in cochlear function following aminoglycoside administration in animals (24, 25) and humans (26) . Simultaneous presentation of two intense, primary tones (fl and f2) to normal cochleae yields many fainter distortion tones. When an fl/f2 ratio of 1.2:1 is presented, the most powerful tone appears at a predictable frequency (2fl-f2) , and is referred to as a 2fl-f2 DPOE. Thus, pairing a 65 dB SPL, 10 kHz tone (fl) with a 50 dB SPL, 12 kHz tone (f2) results in a cochlear emission of a third, 5-10 dB SPL, 8 kHz tone. The ability of a microphone to detect this third, faint tone provides a non-invasive acoustic means of assessing cochlear function (23) . By varying fl and f2, outer hair cell and general cochlear integrity can be evaluated along
the organ of Corti .
Following measurement of the Preyer Reflex, guinea pigs were anesthetized (ketamine 40 mg/kg and xylazine 4 mg/kg) and a CUBDISP™ system (consisting of microphones and high fidelity earphones (Etymotic Research, Oak Grove Village, IL) placed in each ear.
Pairs of continuous tones (65 and 50 dB SPL for fl and f2, respectively) ranging from 1-16 kHz were presented in descending sequences. The 2fl-f2 DPOE together with associated background noise were recorded by the CUBDISP™ system and plotted as a function of stimulus frequency.
The DPOE recorded from saline-treated guinea pigs (n=12) were characteristic of intact cochleae (24) (Figure 3) . The DPOE of animals treated with either neomycin (n=16, Figure 3A,B) or kanamycin (n=16, Figure 3C,D) were indistinguishable from the noise floor, indicative of a severe loss of outer hair cells. Concurrent administration of NMDA antagonists increased DPOE amplitudes well above the noise floor (Figure 3) to values approaching those obtained in control subjects.
Some residual hearing impairment was noted in guinea pigs treated with either neomycin + dizocilpine (Figure 3A) or neomycin + ifenprodil (Figure 3B) manifested as a significant (P<0.01, two-tailed paired t-test) mean decrease of 9.9 and 4.8 dB, respectively, in DPOE amplitudes at 11.5 and 16 kHz. Between these frequencies, a decrement in DPOE amplitudes of 17 and 4.2 dB was also noted in guinea pigs treated with kanamycin and either dizocilpine or ifenprodil, respectively (P<0.01, two- tailed paired t-test) . A region of impaired responsiveness to f2 stimuli of 4 to 8.5 kHz averaging 17- 18 dB (Fig 2C,D) was also observed in guinea pigs receiving kanamycin and either dizocilpine or ifenprodil.
Further assessment of the DPOE data indicated
that 80% (64/80) of the cochleae were within control values in animals receiving concurrent treatment with either dizocilpine or ifenprodil and aminoglycoside (Table 2) . While 100% (28/28) of the DPOE recorded from animals receiving either neomycin or kanamycin were below the noise floor (indicative of total hearing loss) , a similar DPOE was obtained from only one cochlea (1.25%) from guinea pigs treated concurrently with an NMDA antagonist and an aminoglycoside. There was no significant difference in the efficacy of dizocilpine and ifenprodil in this measure, nor was there a significant difference in the incidence (5-30%) of DPOE judged "partially impaired" between control animals and guinea pigs receiving NMDA antagonist +aminoglycosides (Table 2) .
Table 2. NMDA Receptor antagonists attenuate aminoglycoside-induced hearing loss: Effects on DPOE amplitude.
Treatment Number of Ears Normal Partial Complete Loss Tested Hearing Impairment
Saline 12 11 1 0
Neomycin 16 0 0 16**
Kanamycin 12 0 0 12**
Dizocilpine 8 8 0 0
Ifenprodil 8 8 0 0
Dizocilpine + 20 13 6aa 1 Neomycin
Dizocilpine + 20 17 3 0 Kanamycin
Ifenprodil + 20 15 5aa 0 Neomycin
Ifenprodil + 20 19 1 0 Kanamycin
Table 2. Distortion product otoacoustic emissions (DPOE) were measured in male Hartley guinea pigs beginning 5 weeks after initiating ototoxic regimens of neomycin or kanamycin. A complete loss of hearing was defined as a DPOE amplitude within the noise floor. Partial hearing impairment was defined as a DPOE that was significantly lower than normal, but above the noise floor. **: Significantly different from saline values, P<0.01, κ2 test. "*: Significantly different from corresponding antibiotic only group, P<0.01, κ2 test.
° EXAMPLE 3
Male, albino Hartley guinea pigs (250-300 g, Charles River, Raleigh, NC) were maintained under similar conditions, and received the same drug treatments as described in Example 1. 5 After DPOE measurements, some guinea pigs were euthanized with an overdose of chloral hydrate anesthesia. Guinea pigs treated with saline, neomycin, neomycin + dizocilpine, and neomycin + ifenprodil (2 animals/group) were then transcardially perfused with Tyrode's solution 0 followed by mixed aldehydes (2% paraformaldehyde, 2.5% glutaraldehyde) in cacodylate buffer, pH 7.2. The cochleas were removed, fixed overnight in the mixed aldehyde solution, washed and decalcified in 8% EDTA for two weeks . They were then dehydrated and embedded in 5 glycol methacrylate . Using a microtome, serial 4 μm ' ■ sections were cut in the plane of the modiolus ; every 8th section was mounted on a glass slide and stained with toluidine blue prior to coverslipping.
All sections through the organ of Corti were 0 traced using a camera lucida. The numbers of inner and outer hair cells were counted and cytocochleograms constructed showing the number of hair cells along each millimeter of the basilar membrane. Analyses were performed by comparing the number of inner and outer hair 5 cells/mm in each experimental group with the number of inner and outer hair cells/mm in saline control guinea pigs, and expressing the result as percentage of cells missing.
Histological examination of cochleae following 0 treatment with neomycin (Figure 4) revealed a complete
(100%) loss of inner and outer hair cells in half-turns I and II (basal 7 mm of the cochlea) , with severe (30-80%) hair cell loss in half-turns III-IV (7-11 mm from the apex) , and moderate (0-20%) hair cell loss in half-turns <- V-VIII (1-7 mm from the apex, Figure 4) . In contrast,
° only moderate (17-20%) to severe (27-40%) hair cell loss in basal half-turn I was present in guinea pigs receiving neomycin and either dizocilpine (Fig. 3B, 4) or ifenprodil (Figure 4) . In the more apical turns (1-17 mm from the base) of the cochlea, hair cell loss was minor (0-7%) following treatment with either NMDA antagonist, with a considerable reduction in damage to other structural elements of the cochlea compared to neomycin-treated animals (Figure 4) .
EXAMPLE 4
Male, Sprague-Dawley rats (200-300 g, Taconic Farms, Germantown, NY) provided the brain tissue used for the radioligand binding assays. These animals were maintained under similar conditions as described in Example 1 for guinea pigs, but in separate facilities.
Radioligand Binding Assays
Rat cerebral cortex was homogenized in preparation buffers (15,16) with a Polytron (Brinkmann Instruments, Westbury, New York) and extensively "washed" (resuspended and recentrifuged) to remove endogenous materials (e.g. glycine, glutamate, polyamines) that affect radioligand binding to NMDA receptors. Extensively washed membranes were suspended in 5-10 volumes (original wet weight) of 5 mM HEPES/4.5 mM- Tris (HTS) buffer (pH 7.4) at stored at -70°.
[3H] Dizocilpine binding: Forebrain homogenates were thawed, diluted to a concentration of 1:50 with HTS, and washed twice. After the final centrifugation step, the pellet was resuspended in 25 vol of HTS. Assays were performed in duplicate using 1.5 ml plastic microtiter plates and consisted of 50 μl of aminoglycoside or spermine (1-3000 μM) , 300 μl of tissue suspension, 50 μl [3H] dizocilpine (final concentration, 3.5 nM) , and HTS buffer to a volume of 500 μl . Nonspecific binding was
determined using dizocilpine (10 μM) . Incubations were conducted at room temperature and terminated after 2 hours by rapid filtration over Schleicher and Schuell #32 filters (Keene, NH) pretreated with 0.03% polyethylenimine . Filters were rapidly washed with 2 x 2.5 ml of ice cold HTS.
[3H] Ifenprodil binding: Extensively washed cortical homogenates were thawed, diluted to a concentration of 1:50 with HTS, and washed an additional two times. After the final centrifugation step, the pellet was resuspended in 5 volumes of HTS. Assays were performed in (e.g. 12 x 75 mm) glass tubes. Duplicate tubes contained: 50 μl of aminoglycoside (0.1 - 1000 μM) , 50 μl membrane suspension, 50 μl (+) -pentazocine (10 μM, to block σ sites), 50 μl of [3H] ifenprodil (5 nM) and HTS buffer to a final volume of 500 μl . Non-specific binding '" was determined using 10 μM ifenprodil . The assay was incubated at 4°C for 2 hours and terminated by rapid filtration over S+S #32 filters pretreated with 0.03% polyethylenimine. Filters were washed with 2 x 2.5 ml of ice-cold HTS. All binding data were analyzed by nonlinear regression.
Aminoglycoside Modulation of Radioligand Binding to the NMDA Receptor All seven aminoglycosides examined enhanced
[3H] dizocilpine binding to NMDA receptors prepared from rat forebrain (Table 3; Figure 5) . Spectinomycin, which exhibits little or no ototoxicity (27, 28) was >20-fold less potent (EC50=220+42 μM) than the ototoxic aminoglycosides. The potencies of these aminoglycosides to enhance [3H] dizocilpine binding was highly correlated with their relative ototoxicities in humans (2) (Bonferroni-corrected Pearson correlation coefficient: 0.928, P < 0.01, Figure 5B) , with streptomycin a prominent outlier. Endogenous polyamines such as spermine initially
enhance, and at higher concentrations inhibit [3H] dizocilpine binding (29, 30) . Among the ototoxic antibiotics examined, only neomycin, gentamicin and streptomycin exhibited this biphasic effect on [3H] dizocilpine binding (Figure 5A, Table 3), and the potencies (IC50 ) of these antibiotics to produce the secondary inhibition was negatively correlated with their relative ototoxicities in humans (2) (Bonferroni -corrected Pearson correlation coefficient = -0.838, P < 0.01) .
Aminoglycoside antibiotics also inhibit [3H] ifenprodil binding to polyamine-associated sites (15,31) on NMDA receptors with potencies similar to those required to enhance [3H] dizocilpine binding (Table 3a). However, the IC50 values for aminoglycosides in this measure were not significantly correlated with their relative ototoxicities in humans (Bonferroni- corrected Pearson correlation coefficient: 0.36, P = 0.09). Table 3. Aminoglycoside Modulation of [3H]Dizocilpine Binding to NMDA receptors.
Compound EC50, [3H]Dizocilpine, Eraax [3H]Dizocilpine, IC50 [3H]Dizocilpine,
(μM) (% increase) (μM)
Streptomycin 4.9±0.1 92±2.8 570 ±120
Neomycin 6.4±0.3 110+ 14 5700 ± 1200
Amikacin 8.1 ±0.3 110±3.0
Kanamycin 8.3±0.2 140±8.2
Tobramycin 9.5±0.4 120±0.7
Gentamicin 10±0.2 110±7.5 1300±78
Spectinomycin 220 ±42 100±9.7
Spermine 5.3±0.7 110±13 580 ±190
Table 3a Aminoglycoside Modulation of [3H] Ifenprodil Binding to NMDA Receptors.
Compound IC50
[3H]Ifenprodil,
(μM)
Streptomycin 6.2±0.7
Neomycin 4.8±0.3
Amikacin 7.4±0.4
Kanamycin 5.6±0.3
Tobramycin 7.5±0.7
Gentamicin 5.7±0.3
Spectinomycin 230 ±25
Spermine 6.9*
EC50 values are the aminoglycoside concentrations that increase [3H] dizocilpine (3.5 nM) binding to rat forebrain homogenates by 50% of maximum. E,^ is the maximal enhancement of [3H] dizocilpine binding expressed as the % increase above basal (non-stimulated) values . The E^ values were not significantly correlated with relative ototoxicities (Bonferroni-corrected Pearson correlation coefficient: 0.046, P=0.83). IC50 values are presented for those aminoglycosides exhibiting a biphasic effect on [3H] dizocilpine binding. There was no apparent relationship between the IC50 values for inhibition of [3H] ifenprodil binding and the relative ototoxicities of these aminoglycosides. Parameter values were obtained using nonlinear regression fitting of data to sigmoidal curves with the IC50 values for [3H] dizocilpine binding determined by constraining the fit to control levels. Each value represents the mean + SEM of 4 observations.
EXAMPLE 5
A variety of functional NMDA antagonists are tested in humans being treated with the aminoglycosides neomycin, gentamycin and kanamycin.
Patients are treated with 1-3 mg/kg gentamycin 3 times daily for the duration of an infection; 500-2000 mg neomycin 4 times daily for a period of 4 days; or 5-7.5 mg/kg amikacin every 8-12 hr. for the duration of the infection. The functional NMDA antagonists used in combination with these aminoglycosides include at least one of ifenprodil, memantine or dizocilpine.
EXAMPLE 6 The functional NMDA antagonists, dizocilpine and ifenprodil are administered to patients at dosages of 0.1 mg/kg/day and 2 mg/kg/day respectively prior to beginning aminoglycoside treatment. The bacterial infection is cured and the subject suffers no ototoxic damage.
The person of skill in the art will recognize that the invention herein can be modified in ways still within the scope of the invention. All references cited herein and in the section following are hereby incorporated by reference .
REFERENCES
1. Sande, M.A., & Mandell, G.L. The Aminoglycosides, in The Pharmacological Basis of Therapeutics (eds. Goodman-Gilman, A., Goodman, L.S., & Gilman, A.) 1162-1180 (Macmillan, New York 1980). 5 2. Begg, E.J. & Barclay, M.L. Aminoglycosides-
50 years on. Bri t . J. Clin . Pharmacol , 39, 597-603.
3. Brummett, R.E. Fox, K.E. Bendrick, T.W. & Himes, D.L. Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin in the guinea pig. J". Antimicrob . 0 Chemother. 4: 73-83, Suppl A (1978).
4. Stringer, S.P., Meyerhoff, W.L., & Wright, C.G. Ototoxicity in Otolaryngology (eds. Paparella, M.M. , Shumrick, D.A., Gluckman, J.K., & Meyerhoff, W.L.) 1653- 1669 (W.B. Saunders, Philadelphia, 1991) . 5 5. Brummett, R.E., & Morrison, R.B. The
'" incidence of aminoglycoside antibiotic-induced hearing loss. Arch . Otolaryngol . Head Neck Surg. 116, 406-410 (1990) .
6. Jaristedt, J. & Bagger-Sjoback, D. 0 Gentamicin induced changes in RNA content in sensory and ganglionic cells in the hearing organ of the lizard Calotes versicolor: a cytochemical and morphological investigation . Acta Otolargngol . 83, 401-409, (1977).
7. Lim, D.J. Effects of noise and ototoxic 5 drugs at the cellular level in the cochlea. Am. J.
Otolaryngol . 7, 73-99, (1986) .
8. Stockhorst, E., & Schacht, J. Radioactive labeling of phospholipids and proteins by cochlear perfusion in the guinea pig and the effect of neomycin. 0 Acta . Otolaryngol . 83, 401-409 (1977).
9. Safieddine, S., & Eybalin, M. Co-expression of NMDA and AMPA/kainate receptor mRNAs in cochlear neurones. NeuroReport 3, 1145-1148 (1992).
10. Pujol, R., Puel, J-L., D'Aldin, C.G., & <- Eybalin, M. Pathophysiology of the glutamatergic synaoses
° in the cochlea. Acta Otolaryngol . 113, 330-334 (1993). 11. Pullan, L.M. , Stumpo, R.J., Powel, R.J.,
Paschetto, K.A. , & Britt, M. Neomycin is an agonist at a polyamine site on the N-methyl-D-asparate receptor. J".
Neuroche . 59, 2087-2093, 1992. 12. Choi, D.W., Maulucci-Gedde, M., and
Kriegstein, A.R. Glutamate neurotoxicity in cortical cell culture. J. Neurosci . 7, 357-368 (1987).
13. Oliveira, J.A.A. Aminoglycoside antibiotics-Neomycin in Audiovestibular Toxici ty of Drugs (Ed. Oliveria, J.A.A.) 223-244 (CRC Press, Boca Raton, Date) .
14. Bamonte, F., Parravicini, L., Arpini, A. Histological evaluation of ototoxic reaction due to some aminoglycoside antibiotics. Arch Otorhinolaryngol 228, 163-170, (1980) .
'- 15. Hashimoto K. , Mantione, C.R., Spada, M.R. ,
Neumeyer, J.L., & London, E.D. Further characterization of [3H] ifenprodil binding in rat brain. Eur. J. Pharmacol , Mol Pharm Sect, 266, 61 - 71 (1994) . 16. Skolnick, P., Boje, K. , Miller, R. ,
Pennington, M. , & Maccecchini, M-L. Noncompetitive inhibition of N-methyl-D-aspartate by conantokin-G: Evidence for an allosteric interaction at polyamine sites. J. Neurochem . 59, 1516-1521 (1992) . 17. Oliveira, J.A.A. Methods for studying ototoxicity in Audiovestibular Toxici ty of Drugs (ed. Oliveria, J.A.A.) 71-74 (CRC Press, Boca Raton, DATE).
18. Hood, L.J., et al . , Objective auditory threshold estimation using sine-wave derived responses. Hearing Res . 55, 109,-116 (1991).
19. Zhou, L.M., et al . , J". Neurochem. 66:620- 628 (1996) .
20. M. G. Palfreyman, I. J. Reynolds and P. Skolnick, eds., Direct and Allosteric Control of Glutamate Receptors, CRC Press, Boca Raton (1994) .
° 21. B. Scatton, P. Avenet, J. Benavides, C.
Carter, D. Duerger, A. Oblin, G. Perrault, D. J. Sanger, and H. Schoemaker, in : Palfreyman et al . , eds., Direct and Allosteric Control of Glutamate Receptors, Chapter 10, pp. 139-154, CRC Press, Boca Raton, 1994.
5 22. Zhang, L. et al . , Proc . Natl . Acad. Sci .
USA 91:10883-87 (1994).
23. Huang, J-M. Money, M.K., Berlin, C.I., & Keats, B.J.B. Auditory phenotyping of heterozygous sound- responsive (t/dn) and deafness (dn/dn) mice. Hear. Res . 0 88: 61-64 (1995) .
24. Brown, A.M., McDowell, B., & Forge, A. Acoustic distortion products can be used to monitor the effects of chronic gentamicin treatment. Hear. Res . 42, 143-156 (1989) . 5 25. Henley, CM. Kanamycin depletes cochlear polyamines in the developing rat . Otolaryngol . Head Neck Surg. 110, 103-109, (1994) .
26. Revai, K. , Katona, G., Pytel, J. , Czinner, A., & Pataki, L. Evaluation of hearing loss by means of 0 inner ear acoustic emission in neonates with aminoglycoside. Orv. Hetil . 136, 2615-2618, (1995) .
27. Kotecha, B., & Richardson, G.P. Ototoxicity in vitro: effects of neomycin, gentamicin, dihydrostreptomycin, amikacin, spectinomycin, neamine, 5 spermine and poly-L-lysine . Hear. Res . 73, 173-184,(1994).
28. Akiyoshi, M. , Yano, S., & Ikeda, T. Ototoxicity of spectinomycin. Jpn . J. Antibiot . 29, 771- 782, (1976) .
29. Williams, K. , Romano, C, & Molinoff, P. 0 Effects of polyamines on the binding of [3H]MK-801 to the
N-methyl-D-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site. Mol . Pharm . 36, 575-581, (1989) .
30. Chandler, P., Pennington, M. , Maccecchini, <- M., Nashed, N. , & Skolnick, P. Polyamine-like actions of
peptides derived from conantokin-G, an NMDA antagonist. J. Biol . Chem . 268,17173-17178, (1993).
31. Reynolds, I.J., & Miller, R.J. Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines. Mol . Pharm . 36, 758-765, (1989) .
Claims
CLAIMS :
1. A method of preventing or ameliorating aminoglycoside-induced ototoxicity comprising administering to a subject in need of preventing or ameliorating aminoglycoside- induced ototoxicity a
5 therapeutically effective amount of a functional NMDA antagonist .
2. The method of claim 1 wherein the functional NMDA antagonist is administered preceding 0 administration of an aminoglycoside antibiotic.
3. The method of claim 1 wherein the functional NMDA antagonist is administered concurrently with an aminoglycoside antibiotic. 5
4. The method of claim 1 wherein administration of the functional NMDA is continued for up to a month after the cessation of aminoglycoside antibiotic therapy. 0
5. The method of claim 1 wherein the functional NMDA antagonist is a quinoline compound.
6. The method of claim 1 wherein the 5 functional NMDA antagonist is a non-quinoline compound.
7. The method of claim 6, wherein said NMDA receptor antagonist is administered over a period of time corresponding to the two half lives of said aminoglycoside 0 antibiotic.
8. The method of claim 6, wherein the aminoglycoside antibiotic is selected from the group consisting of: <- - gentamycin;
° - streptomycin; kanamycin; and neomycin.
9. The method of claim 6, wherein the non- quinoline NMDA receptor antagonist is selected from the group consisting of: dizocilpine; and ifenprodil .
10. A bacteriocidal antibiotic composition comprising :
(a) a therapeutically effective amount of an aminoglycoside; and
(b) a functional NMDA antagonist provided in a dosage to control ototoxicity.
11. The antibiotic of claim 10, wherein said aminoglycoside is selected from the group consisting of: gentamycin; - streptomycin; kanamycin; and neomycin.
12. The antibiotic composition according to claim 10 wherein said functional NMDA antagonist is capable of acting at an NMDA receptor glycine binding site .
13. The antibiotic composition according to claim 10 wherein said functional NMDA antagonist is capable of acting at an NMDA receptor glutamate binding site.
14. The antibiotic composition according to claim 10 wherein said functional NMDA antagonist is
° capable of acting at an NMDA receptor polyamine/spermine binding site.
15. The antibiotic composition according to claim 10 wherein said functional NMDA antagonist is an NMDA receptor ion channel blocker.
16. The antibiotic composition according to claim 10 wherein said functional NMDA antagonist is selected from the group consisting of:
7-chlorokynurenic acid; indole-2-carboxylic acid; L-687414; HA-966; and - 1-aminocyclopropane carboxylic acid.
I'll . The antibiotic composition according to claim 13 wherein said functional competitive NMDA antagonist is selected from the group consisting of: - 2- (2-carboxypiperazin-4-yl) propyl-1- phosphonic acid; CGP 39653
CGP 40116 LY 274614 and LY 235959
18. The antibiotic composition according to claim 14 wherein said functional polyamine site NMDA antagonist is selected from the group consisting of: diethylenetriamine ; ifenprodil; eliprodil; conantokin-G; and arcaine .
° 19. The antibiotic composition according to claim 15 wherein said functional NMDA antagonist is selected from the group consisting of:
1- [1- (2-thienyl) cyclohexyl] -piperidine; dizocilpine; - ketamine; and memantine.
20. The composition of claim 10, wherein said composition further comprises: a pharmaceutically acceptable carrier.
21. The composition of claims 10, wherein said composition is a solution for parenteral administration.
22. The composition of claims 1, wherein said
• composition is administered orally.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44246/97A AU4424697A (en) | 1996-09-11 | 1997-09-11 | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71247796A | 1996-09-11 | 1996-09-11 | |
US08/712,477 | 1996-09-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998010757A2 WO1998010757A2 (en) | 1998-03-19 |
WO1998010757A3 WO1998010757A3 (en) | 1998-05-14 |
WO1998010757A9 true WO1998010757A9 (en) | 1998-07-23 |
Family
ID=24862272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/016605 WO1998010757A2 (en) | 1996-09-11 | 1997-09-11 | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4424697A (en) |
WO (1) | WO1998010757A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1201234A3 (en) * | 2000-09-21 | 2003-03-12 | Tinnitus Forschungs- und Entwicklungs GmbH | Treatment of diseases with adamantane derivates |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
CN104840416A (en) * | 2005-09-28 | 2015-08-19 | 奥里斯医学股份有限公司 | Medicinal composition for treating internal-ear disease |
EP2792347A1 (en) * | 2005-09-28 | 2014-10-22 | Auris Medical AG | Pharmaceutical compositions for the treatment of inner ear disorders |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
CN101668525A (en) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | New use of glutaminyl cyclase inhibitors |
WO2008113364A2 (en) * | 2007-03-20 | 2008-09-25 | Recepticon Aps | Amino derivatives to prevent nephrotoxicity and cancer |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
PL2200600T3 (en) * | 2007-09-12 | 2012-04-30 | Merz Pharma Gmbh & Co Kgaa | Neramexane for use in the treatment of sub-acute tinnitus |
EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
DK2686313T3 (en) | 2011-03-16 | 2016-05-02 | Probiodrug Ag | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
US20150044200A1 (en) | 2011-12-12 | 2015-02-12 | Otolanum Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
WO2013178763A1 (en) * | 2012-05-30 | 2013-12-05 | Sensorion | Methods for treating vestibulotoxicity |
DK3461819T3 (en) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | GLUTAMINYL CYCLASE INHIBITORS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
ZA9610741B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
-
1997
- 1997-09-11 AU AU44246/97A patent/AU4424697A/en not_active Abandoned
- 1997-09-11 WO PCT/US1997/016605 patent/WO1998010757A2/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Basile et al. | N–Methyl–D–aspartate antagonists limit aminoglycoside antibiotic–induced hearing loss | |
WO1998010757A9 (en) | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity | |
WO1998010757A2 (en) | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity | |
KR101429735B1 (en) | Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity | |
JP6904612B2 (en) | How to treat cochlear synaptic disorders | |
EP2948135B1 (en) | Compositions and methods for the treatment of pervasive development disorders | |
EP2203050B1 (en) | Topical use of r(+)-n-propargyl-1-aminoindan to treat or prevent hearing loss | |
AU2006341983A1 (en) | Use of an NMDA receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity | |
Li et al. | Acoustic trauma increases cochlear and hair cell uptake of gentamicin | |
JP2008169223A (en) | Treatment of optic neuritis | |
RU2377992C2 (en) | Application of phenothiazine derivative to prevent and/or treat hearing loss | |
Viganò et al. | Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children | |
JP5548328B2 (en) | Hyaluronan as a cytotoxic agent, drug presensitizer and chemical sensitizer in the treatment of disease | |
US20200188332A1 (en) | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | |
US6673832B1 (en) | Methods for identifying compounds for treating pain | |
Svensson et al. | Tacrine interacts with an allosteric activator site on α4β2 nAChRs in M10 cells | |
Tan et al. | Potentiation of noise-induced hearing loss by amikacin in guinea pigs | |
Zhao et al. | In vitro galantamine-memantine co-application: mechanism of beneficial action | |
Segal et al. | Polyamine-like actions of aminoglycosides and aminoglycoside derivatives at NMDA receptors | |
EP3174545A1 (en) | Efficient inhibition of hsp27 | |
Parravicini et al. | Comparative ototoxicity of amikacin, gentamicin, netilmicin, and tobramycin in guinea pigs | |
CN109071450A (en) | Dibenzazepine Zhuo compound and its purposes for treating ear disease and illness | |
Bamonte et al. | Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig | |
Pavlidis et al. | Memantine’s action against aminoglycoside-induced ototoxicity | |
Konitsiotis et al. | Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias |